explore -WSS

explore

author：leisure time 2025-10-01 10:38:39 - browse：99

Kuldeep Singh Rajput -- health tech coverage from STAT — Kuldeep Singh Rajput has left his role as CEO of Biofourmis. World Economic Forum

A month after conducting significant layoffs, Biofourmis is out a CEO: Kuldeep Singh Rajput, one of the company’s founders, has quietly stepped down from his role.

A Biofourmis spokesperson confirmed Rajput’s departure to STAT on Wednesday, and said that while the company hunts for a new CEO it will be helmed by a committee of executives overseen by new board member Ben Wanamaker, a partner at Biofourmis investor General Atlantic. The Boston-based company was valued at $1.3 billion following a $320 million Series D financing round which closed last summer and brought big names to Biofourmis: CVS Health was an investor, and Omar Ishrak, former CEO of Medtronic, and Sachin Jain, CEO of the SCAN Health Plan joined the board.

Founded in 2015, Biofourmis has been developing a dizzying array of tech-enabled care offerings, including home-based care services for hospitals, clinical trials support for biopharma companies, and a pipeline of software-based interventions for heart failure and other conditions.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： FDA investigates CAR

WSS

CDC director unscathed in first congressional testimony

Wildfire smoke exposes gaps in outdoor worker protections

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Organ aging and disease risk measured by new blood test

Peter Hotez and the public health issue of online harassment

U.K. Biobank has 500,000 peoples' genome sequences available

Wikipedia

explore

knowledge

Trump demands the U.S. pay no more for drugs than other countries … again

The EPA's new lead rule: How one expert crunched the numbers

In age of alternative facts, a scholarly course on calling out crap

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

At least 13 dead in Texas as scorching temps continue

With clinical trial data readouts, here's how to spot spin

How one medical school became remarkably diverse

As biotech industry slumps, bioscience job market is upside down

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Pediatric cancer treatments threatened by a new FDA policy

knowledge

The EPA's new lead rule: How one expert crunched the numbers

23andMe had bad news about my health. I wish a person had delivered it

George Santos makes 1st court appearance after pleading not guilty to 13 counts

CDC director unscathed in first congressional testimony

Will the market for weight loss drugs really reach $100 billion?

BioMarin wins approval for gene therapy to treat hemophilia A

hotspot

focus

knowledge

hotspot